Ultragenyx Pharmaceutical (RARE) Common Equity (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Common Equity data on file, last reported at -$236.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at -$236.0 million, down 263.89% year-over-year; the trailing twelve-month figure through Mar 2026 was -$236.0 million (down 263.89% YoY), and the FY2025 annual result was -$80.0 million, down 131.37% from the prior year.
• Common Equity declined to -$236.0 million in Q1 2026 per RARE's latest filing, from -$80.0 million in the prior quarter.
• Over five years, Common Equity peaked at $796.4 million in Q1 2022 and troughed at -$236.0 million in Q1 2026.
• A 5-year average of $242.0 million and a median of $220.5 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2026: Common Equity jumped 993.61% in 2024, then plunged 263.89% in 2026.
• A 5-year view of Common Equity shows it stood at $352.0 million in 2022, then decreased by 21.88% to $275.0 million in 2023, then dropped by 7.27% to $255.0 million in 2024, then sank by 131.37% to -$80.0 million in 2025, then slumped by 195.0% to -$236.0 million in 2026.
• Business Quant data shows RARE's Common Equity at -$236.0 million in Q1 2026, -$80.0 million in Q4 2025, and $9.2 million in Q3 2025.